Literature DB >> 9165493

Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia.

J N Joyce1, J H Meador-Woodruff.   

Abstract

The dopamine (DA) hypothesis of schizophrenia, which was based largely on evidence that pharmacological manipulations of DA systems influence the symptoms of schizophrenia, is undergoing a transformation due to our knowledge of the anatomy and pharmacology of additional subtypes of dopamine receptors. New research links the multiplicity of D2-like receptors to divergent neuroanatomic sites of suspected pathology in schizophrenia. We hypothesize that this research suggests that D2 receptors in the basal ganglia are the likely site of extrapyramidal symptoms and not antipsychotic effects. Rather, D3 receptors of the mesolimbic system are a likely site of antipsychotic effects, and D2 and D4 receptors in the medial temporal lobe and limbic cortical areas are the sites of additional antipsychotic effects. This work also suggests that divergent DA receptor circuits are likely associated with the pathophysiology of this disorder.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9165493     DOI: 10.1016/S0893-133X(96)00276-X

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  14 in total

Review 1.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

Review 2.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

3.  Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride.

Authors:  James M Stone; Rodrigo A Bressan; Kjell Erlandsson; Peter J Ell; Lyn S Pilowsky
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

4.  Prominence of the dopamine D2 short isoform in dopaminergic pathways.

Authors:  Z U Khan; L Mrzljak; A Gutierrez; A de la Calle; P S Goldman-Rakic
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

5.  Update on the neurobiology of schizophrenia: a role for extracellular microdomains.

Authors:  D Shan; S Yates; R C Roberts; R E McCullumsmith
Journal:  Minerva Psichiatr       Date:  2012-09-01

Review 6.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

7.  Dopamine selectively inhibits the direct cortical pathway to the CA1 hippocampal region.

Authors:  N A Otmakhova; J E Lisman
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

8.  Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature.

Authors:  James M Stone; John M Davis; Stefan Leucht; Lyn S Pilowsky
Journal:  Schizophr Bull       Date:  2008-02-26       Impact factor: 9.306

9.  Downregulated AKT-mTOR signaling pathway proteins in dorsolateral prefrontal cortex in Schizophrenia.

Authors:  Radhika Chadha; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2020-01-17       Impact factor: 7.853

Review 10.  Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments.

Authors:  Maria D Rubio; Jana B Drummond; James H Meador-Woodruff
Journal:  Biomol Ther (Seoul)       Date:  2012-01       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.